子宫肌瘤剔除术后应用米非司酮防止复发的效果评价  

The Therapeutic Evaluation of Mifepristone on Preventing Recurrence of Uterine Myomas After Myomectomy

作　　者：冉淑芹[1] 申爱方[1] 邓昆[1] 李秀芝[1] 王其美[1] 

机构地区：[1]聊城市第二人民医院,山东临清252600

出　　处：《肿瘤基础与临床》2006年第5期401-402,共2页journal of basic and clinical oncology

摘　　要：目的 评价子宫肌瘤剔除术后应用米非司酮预防复发的效果。方法 将35～40岁行子宫肌瘤剔除术的患者设为观察组，于术后第1次转经时服用米非司酮12．5mg/天，连续3个月，次年再用1疗程；随机选取既往单纯行子宫肌瘤剔除术的有随访资料的病例为对照组。结果 观察组62例，6例复发，较对照组（8／26）显著低（P〈0．05）。观察组51例恢复正常月经，与对照组（16／26）相比差异有统计学意义（P〈0．05）。结论 子宫肌瘤剔除术后服用米非司酮可有效防止复发，改善月经过多症状。Objective To assess the effects of Mifepristone on the prevention of recurrence of uterine myomas after myomectomy. Methods The cases prepared for myomectomy of 35 - 40 years within treatment groups were treated with Mifepristone from first menses after surgery, 12.5 mg each day lasted for 3 months, and repeated for one course of treatment next year. The cases with complete follow-up result after hysterectomy were randomized into control groups. Results The relapse in the first group was 9.68 % （6/62）, significantly lower than that in the second group 30.77 % （8/26）. 51 cases resumed normal menses, which was significant compared with the control groups（ P 〈 0.05） .Conclusions Oral Mifepristone is an effective treatment in preventing recurrence and and improving symptoms of menorrhagia after myomectomy.

关 键 词：子宫肌瘤剔除术 米非司酮 预防 复发 

分 类 号：R737.33[医药卫生—肿瘤] R730.58[医药卫生—临床医学]